Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 24, 2021
Hackensack Meridian Health, New Jersey's largest, most comprehensive and integrated health network, and Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., have entered into a...
May 18, 2021- Data include landmark median progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) in patients, including those with triple-negative breast cancer (TNBC)Eisai today announced results from a real-world study assessing treatment patterns and clinical outcomes with HALAVEN® (eribulin mesylate) injection as a third-line therapy or greater in patients...
-
May 17, 2021Eisai to present more than 25 abstracts including investigational data on oncology pipeline and products
Eisai Inc. announced today the presentation of more than 25 abstracts across various types of cancer from its oncology portfolio during the virtual scientific program of the 2021 American Society...
-
May 6, 2021Applications Based on Progression-Free Survival, Overall Survival, and Objective Response Rate Data From Respective Pivotal Phase 3 Trials
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 6, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug...
-
Apr 29, 2021
Eisai announced today that the European Journal of Cancer published the results from a post hoc analysis of the Phase 3 SELECT study evaluating the impact of lung metastases on overall survival...
-
Apr 19, 2021Lecanemab Phase 3 Clarity AD Clinical Trial Completed Enrollment
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...
-
Apr 16, 2021Twenty-one presentations featuring data and information on investigational lecanemab in early Alzheimer's disease, DAYVIGO® (lemborexant) CIV in insomnia, FYCOMPA® (perampanel) CIII in epilepsy and investigational lorcaserin in Dravet Syndrome
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from the company's deep neurology pipeline and portfolio, including Alzheimer's disease, insomnia and...
Apr 11, 2021Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that its animation “Leave No One Behind－Disease of Neglected People” which features activities for the...
Mar 31, 2021Endometrial Cancer Is on the Rise, Yet Under-Recognized. Black Health Matters, FORCE, SHARE and Eisai Partner to Inspire Women to Listen, Advocate and Put Their Health FirstEisai Inc. announced today the launch of Spot Her—an initiative to end the silence around endometrial cancer, a type of uterine cancer, and inspire women to listen, advocate and put their health...
-
Mar 19, 2021
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., March 19, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced the first presentation of...